Log In
Print this Print this

IL-31 mAb

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHuman mAb against IL-31
Molecular Target Interleukin-31 (IL-31)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationDermatitis
Indication DetailsTreat atopic dermatitis
Regulatory Designation
PartnerMerck KGaA

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today